This is a material catalyst for MNKD, Afrezza's only marketed product now has a major label expansion into a large, needle-averse pediatric population. Traders should watch for prescription volume data over the next 2-4 quarters as a read on commercial uptake. The stock may gap up significantly on this news given the $1.1B market cap and largely adult-only revenue base prior to approval.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $3.77entry
- T+1 · 6mo ago −6.37%α −6.64% · $3.53
- T+5 · 6mo ago −10.88%α −10.58% · $3.36
- T+20 · 5mo ago +12.47%α +14.26% · $4.24
- T+60 · 3mo ago +7.96%α +6.77% · $4.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabetes. This expands Afrezza's addressable population by >350,000 US children/adolescents with diabetes and represents a significant label expansion for MannKind's only marketed product. The approval is based on the Phase 3 INHALE-1 trial and 20+ years of safety data.
Key Facts
- FDA approved Afrezza for children/adolescents aged 6+ with type 1 and type 2 diabetes
- Over 350,000 US children/adolescents have diabetes, mostly type 1 requiring lifelong insulin
- Approval supported by Phase 3 INHALE-1 trial and 20+ years of clinical data
- Eligible patients pay $35/month or less through MannKind Cares
- Afrezza is the only ultra rapid-acting inhaled insulin and was previously approved only for adults (2014)
Financial Impact
Expands TAM by ~350K pediatric diabetes patients in the US; current MNKD market cap ~$1.1B. The pediatric approval likely adds $100-300M+ in peak revenue opportunity (based on typical inhaled insulin penetration) but exact figures are not stated.
Risk Factors
- Afrezza's commercial adoption in adults has been slow since 2014 launch; pediatric uptake may face similar barriers
- Competing with entrenched injectable insulin analogs and pumps; insurance coverage/reimbursement challenges
- Potential lung function concerns in growing children, long-term safety data are limited
- Black-box warning for bronchospasm in patients with chronic lung disease limits target population
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303734 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers